Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007283 | 0.89 | KDM4E (0.45) | KDM4ERAB9ATDP1L3MBTL1MEN1 | |
| SCHEMBL1005669 | 0.87 | GAA (0.48) | AGTR1AGTR2RAB9AMEN1KMT2A | |
| SCHEMBL1008169 | 0.86 | HPGD (0.47) | KDM4ERAB9AL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL1007634 | 0.78 | PTGER4 (0.44) | KDM4ERAB9ATDP1L3MBTL1MEN1 | |
| SCHEMBL13521117 | 0.76 | LMNA (0.62) | ALDH1A1MAPT | |
| SCHEMBL1007553 | 0.75 | HRH3 (0.48) | KDM4ERAB9AL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL10479394 | 0.74 | MAPT (0.48) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8877953 | 0.74 | RARB (0.44) | RARBAGTR1AGTR2MEN1ALDH1A1 | |
| SCHEMBL8410310 | 0.74 | PTGER4 (0.53) | AGTR1AGTR2 | |
| SCHEMBL5806383 | 0.71 | FABP4 (0.49) | RAB9AALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009119088-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | RARB 378/4885AGTR1 98/4885AGTR2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.